Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT07595081
PHASE2/PHASE3
Propionic Acid for Multiple Sclerosis: Safety and Benefits
Sponsor: Salzburger Landeskliniken
View on ClinicalTrials.gov
Summary
The purpose of this study is to explore the long-term safety, tolerability, and clinical efficacy of propionic acid as an add-on therapy in multiple sclerosis (MS).
Official title: Propionic Acid in Multiple Sclerosis: Safety, Tolerability and Clinical Outcomes From the Pro-MADAI Study
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
22
Start Date
2024-08-01
Completion Date
2025-12-12
Last Updated
2026-05-19
Healthy Volunteers
No
Conditions
Interventions
DIETARY_SUPPLEMENT
Propionic acid 1000 mg capsule
Patients will receive propionic acid as add on MS treatment.
Locations (1)
Salzburger Landeskliniken
Salzburg, State of Salzburg, Austria